Malignant mesothelioma

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This phase 2 trial tests brentuximab vedotin (Adcetris) in 55 patients with CD30+ malignant mesothelioma that cannot be removed by surgery. The drug is an antibody-drug conjugate designed to seek out and attack cancer cells carrying the CD30 marker. The main goal is to see if the…

This study tests a new treatment using specially engineered immune cells (called CAR-NK cells) from donated cord blood, given alongside chemotherapy, for people with advanced kidney cancer, mesothelioma, or bone cancer. The goal is to find a safe dose and see if it helps control …

This phase 2b trial tests whether the immunotherapy drug tremelimumab can help people with advanced mesothelioma live longer. About 571 patients who have already tried standard chemotherapy will receive either tremelimumab or a placebo. The main goal is to see if the drug improve…

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the trial was withdraw…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…